- Stocks
- Healthcare
- NASDAQ: PGEN

Price (delayed)

$1.22

Market cap

$311.69M

P/E Ratio

8.71

Dividend/share

N/A

EPS

$0.14

Enterprise value

$309.83M

Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases

PGEN's equity has surged by 149% year-on-year and by 46% since the previous quarter

Precigen's EPS has surged by 129% YoY

PGEN's net income has surged by 126% year-on-year but it is down by 12% since the previous quarter

PGEN's quick ratio has soared by 98% from the previous quarter but it is down by 47% YoY

What are the main financial stats of PGEN

Market
Valuations
Earnings

Shares outstanding

255.48M

Market cap

$311.69M

Enterprise value

$309.83M

Price to earnings (P/E)

8.71

Price to book (P/B)

1.67

Price to sales (P/S)

12.06

EV/EBIT

10.43

EV/EBITDA

7.97

EV/Sales

13.33

Revenue

$23.25M

EBIT

$29.71M

EBITDA

$38.89M

Free cash flow

-$67.7M

Per share
Balance sheet
Liquidity

EPS

$0.14

Free cash flow per share

-$0.29

Book value per share

$0.73

Revenue per share

$0.1

TBVPS

$0.7

Total assets

$241.55M

Total liabilities

$57.41M

Debt

$21.69M

Equity

$184.13M

Working capital

$91.01M

Debt to equity

0.12

Current ratio

2.95

Quick ratio

2.85

Net debt/EBITDA

-0.05

Margins
Efficiency
Dividend

EBITDA margin

167.3%

Gross margin

73.5%

Net margin

106.8%

Operating margin

-325.7%

Return on assets

9.6%

Return on equity

19.5%

Return on invested capital

19.2%

Return on capital employed

15.2%

Return on sales

127.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Precigen stock price performed over time

Intraday

1.67%

1 week

-5.43%

1 month

7.96%

1 year

-8.27%

YTD

-19.74%

QTD

15.09%

How have Precigen's revenue and profit performed over time

Revenue

$23.25M

Gross profit

$17.08M

Operating income

-$75.71M

Net income

$24.83M

Gross margin

73.5%

Net margin

106.8%

PGEN's net income has surged by 126% year-on-year but it is down by 12% since the previous quarter

Precigen's net margin has soared by 119% YoY

PGEN's gross profit has surged by 66% year-on-year but it is down by 17% since the previous quarter

PGEN's operating margin is up by 42% YoY but it is down by 18% from the previous quarter

What is Precigen's growth rate over time

What is Precigen stock price valuation

P/E

8.71

P/B

1.67

P/S

12.06

EV/EBIT

10.43

EV/EBITDA

7.97

EV/Sales

13.33

Precigen's EPS has surged by 129% YoY

PGEN's equity has surged by 149% year-on-year and by 46% since the previous quarter

PGEN's P/B is 77% below its 5-year quarterly average of 7.3 and 44% below its last 4 quarters average of 3.0

PGEN's P/S is 99% below its 5-year quarterly average of 1236.1 and 11% below its last 4 quarters average of 13.5

Precigen's revenue has increased by 42% YoY but it has decreased by 14% from the previous quarter

How efficient is Precigen business performance

The ROIC has soared by 196% YoY and by 22% from the previous quarter

The ROA has soared by 138% YoY but it has contracted by 4% from the previous quarter

Precigen's return on sales has surged by 127% YoY

PGEN's return on equity has surged by 124% year-on-year but it is down by 31% since the previous quarter

What is PGEN's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for PGEN.

How did Precigen financials performed over time

PGEN's quick ratio has soared by 98% from the previous quarter but it is down by 47% YoY

PGEN's current ratio has surged by 97% since the previous quarter but it has dropped by 51% year-on-year

Precigen's debt is 88% less than its equity

PGEN's equity has surged by 149% year-on-year and by 46% since the previous quarter

PGEN's debt to equity has plunged by 96% YoY and by 71% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.